IL143717A0 - Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites - Google Patents

Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites

Info

Publication number
IL143717A0
IL143717A0 IL14371799A IL14371799A IL143717A0 IL 143717 A0 IL143717 A0 IL 143717A0 IL 14371799 A IL14371799 A IL 14371799A IL 14371799 A IL14371799 A IL 14371799A IL 143717 A0 IL143717 A0 IL 143717A0
Authority
IL
Israel
Prior art keywords
ectoparasites
medicament
inhibitors
utilization
caused
Prior art date
Application number
IL14371799A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of IL143717A0 publication Critical patent/IL143717A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/14Ectoparasiticides, e.g. scabicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
IL14371799A 1998-12-17 1999-12-07 Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites IL143717A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19858253A DE19858253A1 (de) 1998-12-17 1998-12-17 Verwendung von Inhibitoren des KQt1-Kanals zur Herstellung eines Medikaments zur Behandlung von Krankheiten, die durch Helminthen und Ektoparasiten hervorgerufen werden
PCT/EP1999/009547 WO2000035429A1 (de) 1998-12-17 1999-12-07 Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden

Publications (1)

Publication Number Publication Date
IL143717A0 true IL143717A0 (en) 2002-04-21

Family

ID=7891421

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14371799A IL143717A0 (en) 1998-12-17 1999-12-07 Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites

Country Status (24)

Country Link
US (2) US6335363B1 (xx)
EP (1) EP1140042B1 (xx)
JP (1) JP2002532412A (xx)
KR (1) KR20010089574A (xx)
CN (1) CN1170528C (xx)
AR (1) AR021690A1 (xx)
AT (1) ATE390130T1 (xx)
AU (1) AU1559500A (xx)
BR (1) BR9916190A (xx)
CA (1) CA2355300A1 (xx)
CZ (1) CZ20012125A3 (xx)
DE (2) DE19858253A1 (xx)
HK (1) HK1041647B (xx)
HR (1) HRPK20010442B1 (xx)
HU (1) HUP0200152A3 (xx)
IL (1) IL143717A0 (xx)
NO (1) NO20012976L (xx)
NZ (1) NZ512408A (xx)
PL (1) PL349511A1 (xx)
RU (1) RU2238090C2 (xx)
SK (1) SK8562001A3 (xx)
TR (1) TR200101750T2 (xx)
WO (1) WO2000035429A1 (xx)
ZA (1) ZA200103620B (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1718677E (pt) * 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
MX2007001470A (es) * 2004-08-05 2007-03-26 Genentech Inc Antagonistas anti-cmet humanizados.
SG185966A1 (en) 2007-06-07 2012-12-28 Divergence Inc Control of ectoparasites
US20100310726A1 (en) 2009-06-05 2010-12-09 Kraft Foods Global Brands Llc Novel Preparation of an Enteric Release System
US9968564B2 (en) 2009-06-05 2018-05-15 Intercontinental Great Brands Llc Delivery of functional compounds
US8859003B2 (en) * 2009-06-05 2014-10-14 Intercontinental Great Brands Llc Preparation of an enteric release system
US20100307542A1 (en) * 2009-06-05 2010-12-09 Kraft Foods Global Brands Llc Method of Reducing Surface Oil on Encapsulated Material
MX2013014687A (es) 2011-06-30 2014-02-17 Genentech Inc Formulaciones de anticuerpo anti-c-met.
US8859005B2 (en) 2012-12-03 2014-10-14 Intercontinental Great Brands Llc Enteric delivery of functional ingredients suitable for hot comestible applications
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
EP2957557A1 (en) * 2014-06-17 2015-12-23 Novartis Tiergesundheit AG New compounds
WO2017136727A2 (en) 2016-02-05 2017-08-10 Denali Therapeutics Inc. Compounds, compositions and methods
ES2912295T3 (es) 2016-12-09 2022-05-25 Denali Therapeutics Inc Compuestos útiles como inhibidores de RIPK1
PE20200608A1 (es) * 2017-06-30 2020-03-10 Bayer Animal Health Gmbh Nuevos derivados de azaquinolina
TW202334164A (zh) 2022-01-12 2023-09-01 美商戴納立製藥公司 (S)-5-苄基-N-(5-甲基-4-側氧基-2,3,4,5-四氫吡啶並[3,2-b][1,4]氧氮呯-3-基)-4H-1,2,4-***-3-甲醯胺的晶型

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1044116C (zh) * 1993-11-29 1999-07-14 默里尔药物公司 用作il-1作用抑制剂的苯磺酰亚胺衍生物及其用途
US5559026A (en) * 1994-10-31 1996-09-24 American Cyanamid Company Genes encoding a novel family of potassium channels
DE19504379A1 (de) * 1995-02-10 1996-08-14 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Präparate sowie sie enthaltende pharmazeutische Präparate
SK283837B6 (sk) 1996-05-15 2004-03-02 Hoechst Aktiengesellschaft Chrómany, spôsob ich prípravy, liečivá, ktoré ich obsahujú, a ich použitie
DE19706675A1 (de) 1997-02-20 1998-08-27 Hoechst Ag Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19707656A1 (de) 1997-02-26 1998-08-27 Hoechst Ag Sulfonamid-substituierte anellierte 7-Ring-Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
DE19742508A1 (de) 1997-09-26 1999-04-01 Hoechst Marion Roussel De Gmbh Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
DE19742509A1 (de) 1997-09-26 1999-04-01 Hoechst Marion Roussel De Gmbh Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
DE19748469A1 (de) * 1997-11-03 1999-05-06 Hoechst Marion Roussel De Gmbh Sulfonamid-substituierte Benzopyranderivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
KR20010089574A (ko) 2001-10-06
HK1041647A1 (en) 2002-07-19
CA2355300A1 (en) 2000-06-22
WO2000035429A1 (de) 2000-06-22
HUP0200152A3 (en) 2003-01-28
SK8562001A3 (en) 2001-12-03
EP1140042B1 (de) 2008-03-26
EP1140042A1 (de) 2001-10-10
JP2002532412A (ja) 2002-10-02
HRP20010442A2 (en) 2002-06-30
NO20012976D0 (no) 2001-06-15
CN1330540A (zh) 2002-01-09
NZ512408A (en) 2003-10-31
NO20012976L (no) 2001-08-06
ZA200103620B (en) 2002-06-04
HUP0200152A2 (hu) 2002-05-29
US6335363B1 (en) 2002-01-01
DE19858253A1 (de) 2000-06-21
AR021690A1 (es) 2002-07-31
HRPK20010442B1 (en) 2003-10-31
TR200101750T2 (tr) 2002-01-21
BR9916190A (pt) 2001-09-11
CZ20012125A3 (cs) 2001-09-12
RU2238090C2 (ru) 2004-10-20
DE59914712D1 (de) 2008-05-08
HK1041647B (zh) 2005-04-01
AU1559500A (en) 2000-07-03
PL349511A1 (en) 2002-07-29
CN1170528C (zh) 2004-10-13
US20020055537A1 (en) 2002-05-09
ATE390130T1 (de) 2008-04-15

Similar Documents

Publication Publication Date Title
HRPK20010442B1 (en) Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites
ID25824A (id) Formulasi terapeutik untuk memberikan tolterodin dengan pelepasan yang terkendali
DK2052714T3 (da) Topisk gel-fremføringssystem til behandling af hudlidelser
DK1268481T3 (da) Inaseinkibitorer som terapeutiske midler
BR9707425A (pt) Composto processo terapêutico para inibir o crescimento de células cancerosas e processo para utilizar o composto
GB9803084D0 (en) Improvements relating to medical injection devices
GB9808408D0 (en) Improvements relating to injection devices
EE04390B1 (et) Paikne preparaat dermatoloogiliste seisundite raviks
GB0401948D0 (en) Topical composition for treating pain
EP1438020A4 (en) TOPICAL COMPOSITIONS AND METHOD FOR TREATING PAIN
DK0925022T3 (da) Forbedringer med relation til hudprikkenåle
ATE436065T1 (de) Interaktives wettsystem zum wetten nach kriterien
AU7138601A (en) Methods of treating neutrophil-related diseases with topical anesthetics
IS6575A (is) Hýdroxýfenýl-píperidín-4-ýlíden-metýl-bensamíðafleiður til að meðhöndla sársauka
ID28441A (id) Terapi untuk memperbaiki kesadaran
HK1039555A1 (en) Device for targeted topical treatment of disease
ATE232378T1 (de) Reinigungspflaster zur verbesserung des hautzustandes
PL339836A1 (en) Phtalazine compounds and therapeutic agents suitable to treat erection disorders
ZA978400B (en) Use of inhibitors of the activity of retinoic acid to promote healing.
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
IS6563A (is) Hýdroxýfenýl-píperasinýl-metýl-bensamíðafleiður til að meðhöndla sársauka
IS6574A (is) Kínólinýl-píperidín-4-ýlíden-metýl-bensamíðafleiður til að meðhöndla sársauka
IL138601A0 (en) Pyrrolidines as inhibitors of neuraminidases
ITMI980333U1 (it) Struttura perfezionata di suola adatta alla traspirazione
IL141056A0 (en) Protease inhibitors for use in the treatment of psoriasis

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees